Bristol-Myers Squibb Co. (BMY) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where th...
Bristol-Myers Squibb Co.'s revenue decreased 0.2% year over year, from $48.30B to $48.19B.
Net income increased 178.8% over the same period, from $-8.95B to $7.05B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 148% in total.
Total debt decreased by 9.1% to $45.11B.
The debt-to-equity ratio stands at 2.44, indicating a high leverage profile.
Operating cash flow declined 6.8% to $14.16B.
Bristol-Myers Squibb Co. maintains a healthy net profit margin of 14.6%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $11.89B-2.5% | $1.21B | $8.94B | $2.20B | $5.59B | $93.67B | $49.75B | $17.14B |
| Q4 FY2024 | $12.34B+3.8% | $72.0M | $7.53B | $2.75B | $4.44B | $92.60B | $49.65B | $16.34B |
| Q1 FY2025 | $11.20B-9.2% | $2.46B | $8.17B | $2.97B | $1.95B | $92.43B | $49.71B | $17.39B |
| Q2 FY2025 | $12.27B+9.5% | $1.31B | $8.90B | $1.77B | $3.92B | $94.68B | $49.19B | $17.43B |
| Q3 FY2025 | $12.22B-0.4% | $2.20B | $8.79B | $3.11B | $6.31B | $96.89B | $48.98B | $18.55B |
| Q4 FY2025 | $12.50B+2.3% | $1.09B | $8.40B | $1.47B | $1.97B | $90.04B | $45.11B | $18.47B |
| Q1 FY2026 | $11.49B-8.1% | $2.68B | $8.07B | $3.24B | $1.10B | N/A | N/A | N/A |
| Q2 FY2026 | $12.97B+12.9% | $3.32B | $9.25B | $5.02B | $3.39B | N/A | N/A | N/A |
Balance Sheet Summary (FY2025)
Bristol-Myers Squibb Co. (BMY) Financial Statements & Revenue History
Bristol-Myers Squibb Co. (BMY) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry trading at $60.19 with a market capitalization of $123. This page provides 42 historical financial statements for Bristol-Myers Squibb Co., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Bristol-Myers Squibb Co. reported revenue of $48.2 billion, a 0.2% decline from the prior year. The net profit margin of 14.6% indicates moderate profitability. The debt-to-equity ratio of 2.44 signals high leverage.
BMY Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Bristol-Myers Squibb Co.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether BMY is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track BMY's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Bristol-Myers Squibb Co. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of BMY's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use BMY Financial Data
Investors use Bristol-Myers Squibb Co.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare BMY's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how BMY's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View BMY's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Bristol-Myers Squibb Co.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.BMY trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.